US Patent

US12233106 — C-type natriuretic peptide variants to treat skeletal dysplasia in children

Method of Use · Assigned to Biomarin Pharmaceutical Inc · Expires 2042-07-11 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using variants of C-type natriuretic peptide to treat skeletal dysplasias in children.

USPTO Abstract

treatment of skeletal dysplasias in children, and improvement in one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, by administering variants of C-type natriuretic peptide (CNP) is described.

Drugs covered by this patent

vosoritide (VOSORITIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3927`	—	vosoritide
`U-3927`	—	vosoritide
`U-3927`	—	vosoritide

Patent Metadata

Patent number: US12233106
Jurisdiction: US
Classification: Method of Use
Expires: 2042-07-11
Drug substance claim: No
Drug product claim: No
Assignee: Biomarin Pharmaceutical Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.